4.10
-0.12(-2.84%)
Currency In CAD
Sector
Healthcare
Industry
Biotechnology
Employees
11
First IPO Date
March 15, 2019
| Name | Title | Pay | Year Born |
| Mr. Michael P. Kelly | Chief Executive Officer, President & Director | 1.11M | 1965 |
| Mr. William J. Adams C.A., CPA, CA, CPA | Chief Financial Officer & Corporate Secretary | 483,683 | 1962 |
| Dr. Daniel D. Mikol M.D., Ph.D. | Chief Medical Officer | 767,900 | N/A |
| Mr. Brian McAlister | Co-Founder & Advisor | 0 | N/A |
| Dr. Charles V. Olson D.Sc. | Senior Vice President of Technical Operations | 0 | 1957 |
| Mr. Kevin M. Rooney | Senior Vice President of Corporate Development & Strategy | 0 | 1966 |
| Mr. William Joseph Radvak BASc | Co-Founder & Advisor | 0 | 1963 |
| Dr. Harold Martin Punnett D.M.D. | Co-Founder & Independent Director | 0 | N/A |
| Ms. Elizabeth Eberhardt B.Sc. | Senior Vice President of Program Management | 0 | N/A |
NervGen Pharma Corp., together with its subsidiaries, engages in the discovery, development, and commercialization of pharmaceutical treatments for medical conditions related to nervous system damage. Its lead product candidate is NVG-291 that is in phase 1 clinical trial for the treatment of spinal cord injuries (SCI), multiple sclerosis, and Alzheimer's disease. The company has a licensing agreement with Case Western Reserve University to research, develop, and commercialize a patented technology with therapeutic potential for SCI and other conditions associated with nerve damage. NervGen Pharma Corp. was incorporated in 2017 and is based in Vancouver, Canada.